In summary, the possibility that in KRAS and BRAF mutant cancer cells differential signalling mechanisms that involve MEK supported the mutual exclusivity of these two mutations, lead to the target-specific cancer therapeutics in the form of monoclonal antibodies against EGF and VEGF receptors. This evidence concerns the gene BRAF and cancer.